Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label setmelanotide study in rare genetic obesity disorders
MOH_2020-06-19_008998Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Apr 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setmelanotide in No canonical full name exists for "genetic obesity." and hyperphagia, sponsored by Rhythm Pharmaceuticals. Started Apr 2020; status: completed.
02
Drugs
setmelanotide
03
Conditions
No canonical full name exists for "genetic obesity."hyperphagia
Beyond the preview
Go deeper on MOH_2020-06-19_008998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-19_008998.